Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

ISTITUTO ONCOLOGICO VENETO

🇮🇹Italy

Country: 🇮🇹Italy

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.ioveneto.it

Clinical Trials

Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients

Not Applicable

Not yet recruiting

Conditions: Glioblastoma
IDH Wild-type and STAT3-positive Glioblastoma

First Posted Date: 2025-05-09

Last Posted Date: 2025-06-26

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 110

Registration Number: NCT06964815

Locations: 🇮🇹
IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, BO, Italy
🇮🇹
IRST Dino Amadori, Meldola, FC, Italy
🇮🇹
Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco ", Catania, Italia/Catania, Italy

and more 13 locations

Assessing Financial Toxicity Using the PROFFIT Questionnaire in Patients Treated With Mini-invasive Approach for Urological Malignancies.

Recruiting

Conditions: Prostate Cancer
Bladder Cancer
Kidney Cancer

First Posted Date: 2025-05-02

Last Posted Date: 2025-06-24

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 120

Registration Number: NCT06955910

Locations: 🇮🇹
Istituto Oncologico Veneto, Padova, Italy/Padova, Italy

Preventive Application of Single-use Negative Pressure Wound Therapy (sNPWT) in the Postoperative Course of Radiotreatated Limb Sarcoma Surgery

Not Applicable

Not yet recruiting

Conditions: Sarcoma
Sarcoma,Soft Tissue

First Posted Date: 2025-04-23

Last Posted Date: 2025-05-01

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 48

Registration Number: NCT06941194

Locations: 🇮🇹
Istituto Oncologico Veneto, Padova, Italy/Padova, Italy

Scarless Advanced Breast Extended Oncoplasty: The ScarABEO Study

Recruiting

Conditions: Breast Cancer
Oncoplastic Breast Surgery
Chest Wall Perforator Flap
Oncoplastic Breast-conserving Surgery

First Posted Date: 2025-04-02

Last Posted Date: 2025-04-17

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 250

Registration Number: NCT06906237

Locations: 🇮🇹
Veneto Institute of Oncology, Padova, Italy

Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype

Not Applicable

Not yet recruiting

Conditions: Primary Visceral Tumors of Any Histotype
Visceral Lesions
Liver Cancer
Liver Metastasis Colon Cancer
Melanoma
Primary Pancreatic Tumor
Retroperitoneal Sarcoma
Abdominal and/or Peritoneal Localizations
Merkel Cell Carcinoma
Squamous Cell Carcinoma

First Posted Date: 2024-12-31

Last Posted Date: 2025-04-17

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 24

Registration Number: NCT06753136

Locations: 🇮🇹
Istituto Oncologico Veneto, Padova, Italy

GISEL:Registry of Breast Cancer Patients Treated With ECT

Completed

Conditions: Breast Cancer
Breast Cancer Recurrent
Breast Cancer Metastatic

Interventions: Device: Electrochemotherapy (ECT)
Drug: Bleomycin

First Posted Date: 2024-11-11

Last Posted Date: 2024-11-11

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 205

Registration Number: NCT06683404

Locations: 🇮🇹
Veneto Institute of Oncology IRCCS, Padova, Italy

Novel Therapeutic Approach for Human T-cell Malignancies

Recruiting

Conditions: T-Cell Leukemia/Lymphoma, Adult

First Posted Date: 2024-09-19

Last Posted Date: 2024-09-19

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 120

Registration Number: NCT06600568

Locations: 🇮🇹
Istituto Nazionale Tumori Fondazione G.Pascale, Napoli, Italy
🇮🇹
Istituto Oncologico Veneto, Padova, Italy

Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients with Lung Cancer

Not Applicable

Recruiting

Conditions: Carcinoma, Non-small Cell Lung Cancer (NSCLC)

Interventions: Diagnostic Test: Plasma- SeqSensei™ Solid Cancer IVD Kit (Sysmex)
Diagnostic Test: cobas® EGFR Mutation Test v2 (Roche)

First Posted Date: 2024-09-13

Last Posted Date: 2024-09-13

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 118

Registration Number: NCT06595498

Locations: 🇮🇹
Istituto Oncologico Veneto, Padova, Italy

Immune Microenvironment and Gene Expression Profiling in Mesothelioma

Recruiting

Conditions: Mesothelioma
Mesotheliomas Pleural
Mesothelioma; Lung

First Posted Date: 2024-09-03

Last Posted Date: 2025-06-05

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 220

Registration Number: NCT06581549

Locations: 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milano, Italy
🇮🇹
Centro di Riferimento Oncologico (CRO) IRCCS, Aviano, Pordenone, Italy
🇮🇹
Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

and more 7 locations

Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial)

Phase 2

Recruiting

Conditions: Meningioma, Malignant

Interventions: Drug: Regorafenib 40 MG Oral Tablet
Drug: Local Standard of Care

First Posted Date: 2024-02-23

Last Posted Date: 2025-03-13

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 104

Registration Number: NCT06275919

Locations: 🇮🇹
IRST Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Forlì-Cesena, Italy
🇮🇹
Azienda Ospedaliera Universitaria Gaetano Martino, Messina, Italia/Messina, Italy
🇮🇹
Humanitas Cancer Center, Rozzano, Milano, Italy

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy